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Polycystic ovary syndrome (PCOS) is a common and complex endocrine disorder affecting 5-10% of women in
reproductive age that is characterized by hyperandrogenism, oligo- or anovulation and infertility. However the
pathophysiology of PCOS still remains unknown. The mammalian target of rapamycin (mTOR) is a central
component that regulates various processes including cell growth, proliferation, metabolism, and angiogenesis.
mTOR signaling cascade has recently been examined in ovarian follicles where it regulates granulosa cell
proliferation and differentiation. mTOR functions as two complexes, mTOR complex 1 and 2. Therefore, we
hypothesized that mTORC1 and/or 2 may have important role in proliferation of theca and granulosa cells in PCOS.
In the present study, we sought to determine the mTOR signaling pathway in PCOS mouse ovary. We designed 3
groups: Control (C, no treatment), PCOS (P, The injection of DHEA (6 mg/100 g BW in 0.1 ml of sesame oil) (s.c) for
20 consecutive days), Vehicle (V, daily (s.c) sesame oil alone injection). Our results showed that mTORC1 and
mTORC2-mediated signaling may play a role in PCOS mouse ovary. These findings provide evidence that mTORC1
and mTORC2 may have responsibility in increased ovarian follicular cell proliferation and growth in PCOS.
Consequently, these results suggest that the mTOR signaling pathways (mTORC1 and mTORC 2) may create new
clinical strategies to optimize developmental competence of PCOS should target correction of the entire follicle
growth, oocyte development process and anovulatory infertility in PCOS.
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Polycystic ovarian syndrome (PCOS) a complex, multi-
factorial endocrinopathy which affects approximately 5
to 10% of reproductive-aged women, is the most com-
mon cause of anovulatory infertility. Because it is a
highly heterogeneous syndrome with a variable clinical
presentation, criteria for diagnosis have been debated.
The disease begins at menarche, and symptoms gener-
ally include oligomenhorrhea, amenorrhea, anovulation,
numerous antral follicles, hypersecretion of circulating
LH but with lower or equivalent FSH levels, obesity, hir-
sutism, and insulin resistance [1]. Additionally, PCOS in-
clude hypothalamic-pituitary dysynchrony, aberrant
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distribution, and reproduction in any mediumdysfunction, and various metabolic derangements in-
cluding exaggerated ovarian androgen production,
hyperinsulinemia, and insulin resistance [2-7]. The antral
follicles produce high levels of androstenedione, testos-
terone, and 17αOH-progesterone. The cysts themselves
are remnants of atretic follicles, fluid filled and devoid of
granulosa cells. Polycystic ovary syndrome (PCOS) is the
most common cause of anovulatory infertility [8]. Al-
though the mechanism of anovulation remains uncer-
tain, it is known that genetic and environmental factors
play a role in the origin and development of this dis-
order [9-11]. The endocrine manifestations of PCOS
include increased androgen production of ovarian and/
or adrenal origin and arrested follicular development
leading to chronic oligo- or anovulation [9]. Many au-
thorities utilize the guidelines of Rotterdam/ASRM-
sponsored PCOS Consensus Workshop Group [12] and
require the presence of at least two of the following:tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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or biochemical hyperandrogenism, and the presence of
polycystic ovarian morphology during ultrasound
examination.
The disrupted hypothalamic-pituitary synchrony, inc-
reased gonadotropin pulsatile secretion, destroyed
oocyte-granulosa cell interaction, increased ovarian an-
drogen production, hyperinsulinemia, and insulin resist-
ance included the etiologies of PCOS [13]. Studies
confirmed that the DHEA-treated PCOS murine model
exhibits many of the salient features of human PCOS
[14,15]. The dehydroepiandrosterone (DHEA) is one of
the most abundant circulating androgens in women with
PCOS. Histological examination of ovaries from the
DHEA-treated mice reveal different size of preantral and
antral follicles with a thickened layer of hyperfunctional
theca cells and a compacted formation of granulosa cells
in the ovarian cortex. Additionally, DHEA-treated mice
show increased serum estradiol and progesterone levels
because of the high level circulating androgens [16]. The
objective of this study was to determine the effects of
androstenedione on mTOR signal during ovarian follicu-
lar growth and development. Thus, the present study
was designed to study the possible role of mTOR com-
plexes in PCOS mouse model. In order to determine
how the functionality of ovarian tissue was modified
with cystogenesis, the endocrine markers serum proges-
terone (P) and estradiol (E) were evaluated.
The mammalian target of rapamycin (TOR) gene
product is a ubiquitous serine/threonine kinase that has
been implicated in the control of different stressors,
growth factors, nutrients, and hormones, which partici-
pates in the control of key cellular functions, including
cell proliferation, growth, and metabolism [17-21].
mTOR forms two functionally distinct multiprotein
complexes, mTORC1 and mTORC2, each of which has
defined roles in the control of cell growth and fate
[17,22]. mTORC1, which is rapamycin-sensitive com-
plex, is composed of mTOR, Raptor, and mLST8 (also
called GβL). Additionally, mTORC1 associates with
PRAS40 (proline-rich Akt/protein kinase B (PKB)),
FK506-binding protein 38 (FKBP38) and Rag GTPases.
mTORC2, which is rapamycin-insensitive and growth-
factor-responsive, consists of mTOR, Rictor, Sin1,
mLST8, and PRR5/PRR5L (Protor 1/Protor 2). PRR5 is
not required for the interaction between mTOR, Rictor,
Sin1, and mLST8 [23-25]. mTORC1 and mTORC2
signal via distinct pathways to control a wide variety
of cellular processes. These mTOR-regulated processes
mediate the accumulation of cellular mass and thereby
ultimately determine cell size. The processes controlled
by mTOR include, but are not limited to, translation,
ribosome biogenesis, nutrient transport, autophagy
and AGC (cAMP-dependent protein kinase (PKA)/protein kinase G (PKG)/protein kinase C (PKC)) kinase
activation.
mTOR signaling has been shown to have important
role in the control of puberty onset, gonadotropin secre-
tion, and they showed rapamycin treatment decrease LH
secretion in the female rats [26]. We previously demon-
strated that mTOR acts as a novel mitotic survival
checkpoint to regulate follicle growth in vivo [27].
Therefore, we suggested that mTOR may have respon-
sible excess granulosa and theca cell proliferation and
hormonal dysfunction in PCOS. Here, we aimed to de-
termine mTOR signal proteins in DHEA-treated PCOS
mouse model. Thus, we have chosen to start DHEA
treatment of mice at the prepubertal age of 25 days in




The studies included in this work were performed in ac-
cordance with the Akdeniz University Institutional Ani-
mal Care and Use Committee Policies for Animal Use
under an approved animal protocol. Handling and eu-
thanasia of mice were performed per the Akdeniz Uni-
versity Institutes of Health Guide for the Care and Use
of Laboratory Animals. The hyperandrogenized environ-
ment of PCOS was reproduced in mice by injection of
DHEA [16,28,29]. Briefly, 15 female prepuberal (25 days
old) mice of the Balb/C strain were daily injected (sc)
with DHEA (IL,USA) (6 mg/100 g body weight, dissolved
in 0.01 ml 95% ethanol [30,31] and mixed with 0.09 ml
sesame oil) for 20 consecutive days (DHEA-treated
PCOS group, (P)). The control group consisted of 15
mice injected with 0.09 ml sesame oil and 0.01 ml 95%
ethanol daily for 20 consecutive days (oil group (vehicle
(V))) and 15 untreated mice (control group (C)). All of
these mice were raised and housed under controlled
temperature (22°C) and illumination (14 h light: 10 h
dark; lights on at 05:00 hours). After 20 days of treat-
ment, animals were killed using cervical dislocation after
ketamine anesthesia. After their removal, the ovaries
were immediately fixed with fresh 4% paraformaldehyde
for 6 hours for immunostaining.
Morphological studies
To study the effect of DHEA on cyst formation, ten
ovaries from the control group and ten from DHEA-
treated, and 10 from vehicle group, fixed as described
above, were embedded and samples were cut into 5 μm
sections and deparaffinized in xylene and rehydration in
a graded series of ethanol's. Afterwards sections were
stained with hematoxylin and eosin (DAKO Corpor-
ation, Carpinteria, CA, USA) for histological analysis of
cyst formation.
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Blood for hormonal determinations was obtained by car-
diac puncture from mice treated with DHEA and in
proestrous and estrous control mice. After centrifuga-
tion, plasma was stored at -20°C until assayed. The levels
of 17β-estradiol and progesterone were determined for
each plasma sample. Serum Estrogen (ERK R7005,
Endocrine Technologies) and Progesterone (ERK R7011,
Endocrine Technologies) levels were determined by
ELISA. We used μQuant Scanning Microplate Spectro-
photometer 450 nm wave length.Immunostaining for mTOR and P-mTOR
mTOR and P-mTOR protein expression detected in par-
affin sections. Paraffin-embedded samples were cut into
5 μm sections were collected on poly-L-lysine coated
slides (Sigma, St. Louis, MO, USA) and incubated over-
night at 56°C. Tissue sections were deparaffinized in xy-
lene and rehydration in a graded series of ethanol’s,
antigen retrieval was performed by microwaving in
EDTA (pH: 8.0). For colorimetric detection of mTOR
and P-mTOR, sections were immersed in 3% hydrogen
peroxide in methanol for 10 minutes to block endogen-
ous peroxidase activity. Slides were then incubated in a
humidified chamber with TBS-T (Tris-buffered saline
containing 0.1% Tween-20 and 5% normal goat serum;
Sigma, St Louis, MO) for 1 hour at room temperature.
After removing excess blocking solution, the sections
were incubated with rabbit anti-mouse mTOR (1:100 di-
lution; Cell Signaling Technology, Danvers, MA) over-
night in a humidified chamber at 4°C. The sections were
washed 3 times for 5 minutes each with TBS-T and then
incubated in biotinylated anti-rabbit secondary antibody.
Incubation in streptavidin–horseradish peroxidase
(HRP) conjugates (ABC Elite HRP staining kit; Vector
Laboratories, Burlingame, CA) followed for 30 minutes.
After washing, the sections were incubated in DAB
(Sigma).
For double staining with P-mTOR, after developing
mTOR immunoreaction with DAB, the sections were re-
incubated with primary antibody against P-mTOR over-
night in a humidified chamber at 4°C. Afterwards, the
sections were incubated with a biotinylated secondary
antibody (K0676; Dako), followed by a streptavidin-
alkaline phosphatase complex (K0676; Dako) for 20 min
each. Slides were developed in Fast Red chromogen
(Dako Fast Red Substrate System; K0699; Dako) counter-
stained with Mayer’s Hematoxylin (S3309; Dako). For
controls, sections were treated with appropriate mouse
IgG diluted to the same final protein concentration as
the primary antibody. Photomicrographs were taken
with an Axioplan microscope (Zeiss, Oberkochen,
Germany).Western blot analysis
Total protein from the ovary tissues (n = 10) from each
group were extracted using T-PER tissue protein extraction
reagent (Pierce, Rockford, IL, USA), supplemented with
protease inhibitor cocktail (1 mM Na3VO4, 10 μg/ml
leupeptin, 10 μg/ml aprotinin and 1 mM phenylmethyl-
sulphonylfluoride; Calbiochem, San Diego, CA, USA).
The protein concentration was determined by Bio-Rad
Protein Assay (Bio-Rad Laboratories, Hercules, CA,
USA). Western blot analysis was performed as described
previously [32]. Briefly, 20-μg of protein was loaded into
each lane, separated electrophoretically by SDS–PAGE
using 7.5% Tris–HCl gels, and electroblotted onto nitro-
cellulose membrane (Bio-Rad Laboratories). The mem-
brane was blocked with 5% non-fat dry milk in TBS-T
buffer (0.1% Tween-20 in Tris-buffered saline) for 1 h to
reduce the non-specific binding. The membrane was
then incubated with rabbit polyclonal mTOR antibody
(1:1000 dilution; Cell Signaling Technology, Danvers,
MA, USA) overnight at 4°C, and washed three times with
TBS-T for 20 min. Then, the membrane was incubated
for 1 h with peroxidase-labeled goat anti-rabbit IgG
(Pierce; USA) and subsequently washed with TBS-T
three times for 20 min. mTOR protein expression was
detected using chemiluminescence detecting reagents
(Perkin Elmer Life Sciences, Boston, MA, USA) and
exposure of the membrane to BioMax film (Kodak,
Rochester, NY, USA).
We repeated same procedure for P-mTOR (Serin-
2448), P-mTOR (Serin-2481), Raptor, Rictor, P70S6K,
Phospho-P70S6K, PKCα, Phospho–PKCα and SET8
(PCNA). We used β-actin for internal control.
RT-PCR
For reverse transcription polymerase chain reaction (RT-
PCR), RNA was extracted from whole ovaries as follows
(n = 10). Total ovary tissue homogenized in 1 ml of Tri-
zol Reagent (Invitrogen), followed by RNA extraction.
Reverse transcription was performed upon 1 μg of total
RNA using Superscript II Reverse Transcriptase accord-
ing to the manufacturer’s protocol. PCR reaction was
carried out in 25-μl reaction. PCR was performed using
2 μl of each RT sample within a reaction mix containing
1X Buffer D, 10 pmol of each primer, and Taq Polymer-
ase. All PCR reactions were performed using a hot start
at 95°C for 5 minutes. 35 PCR cycles were performed for
all target genes and control β-actin. Primers used for the
amplification of gene mTOR, Raptor, Rictor, LST8
(GβL), P70S6K and PKCalpha were as follows (oligo-
nucleotide sequences listed 5’ to 3’ orientation and prod-
uct size follow gene name). All primers were designed
such that a genomic exon was spanned, and mock
reversed-transcribed control samples were run versus
every experimental sample (Table 1).
Table 1 Primers list
mTOR 150 bp forward, TTG GAG TGG CTG GGT GCT GA
reverse, AAG GGC TGA ACT TGC TGG AA
Raptor 148 bp forward, GCC ATC ACAGAT ACC ATC GC
reverse, CTG CTT ACT GGGGTG CAG TT
Rictor 110 bp forward, GAG AAC GTC CCG CTC GAT CT
reverse, TGG CCCAGC TTT CTC ATA TT
LST8 (GβL) 138 bp forward, GAC TAA GGC AGA GTG CAG AG
reverse, AAA AGC GCA CCG TGT GGT CA
P70S6K 300 bp forward, CTTGGCGAAT TAAGGGCTGC
reverse, GCATAGGCCAGTTCTACAAT
PKCalpha 300 bp forward, GTCCTGCACCGGTTGGCGAA
reverse, GACCCACAGTGATCACAGAA
β-actin 399 bp forward, GAT GAC GAT ATC GCT GCG CTG
reverse, GTA CGA CCA GAG GCA TAC AGG
Figure 1 Morphological comparison of control and DHEA-treated PCO
from control ovary. C, DHEA-treated PCOS mouse ovary; showed different s
preantral follicle and atretic follicles. D, Follicular cyst (FC) structure from DH
characterized by a thin layer of theca cells and a compacted formation of g
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Groups were compared by one-way ANOVA followed
by post hoc Holm-Sidak test. Statistical calculations were
performed using Sigma Stat for Windows, version 3.0





The general appearance of the control group ovary
resembles normal histology and a peripheral cortex con-
taining large numbers of follicles in various stages of de-
velopment. We observed follicular developmental
synchronization and compact stromal tissue between the
developing follicles (Figure 1A). Oocytes in the follicles
present normal healthy morphology. Medullar region
shows normal vessels network areas in the center of
ovary. We also detected corpus luteum (CL) structure in
the control group ovary (Figure 1A and B).
Histological examination the cortex of ovaries from
DHEA-treated mice showed different stage developing
follicles but an increase in the number of antralS mouse ovary. A, control ovary; B, Corpus Luteum (CL) structure
tage developing follicles but an increase in the number of cysts,
EA-treated PCOS mouse ovary. The morphology of cysts is
ranulosa cells.
Figure 2 Atretic follicles from different stage of follicular development in DHEA-treated PCOS mouse ovary. Unhealthy oocytes have
seen with degenerated cytoplasm and zona pellucida (A–D). The arrows show early preantral follicles with compact oocytes and zona pellucida
(Figure B and D).
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We observed degenerated granulosa cells and oocytes in
atretic follicles (Figure 2A–D). We detected unhealthy
primary oocyte morphology in PCOS group. Histological
analyses revealed the absence of corpora lutea (CL) in
PCOS ovary (Figure 1C and D), which showed also
abundant antral follicle and small atretic follicles, in con-
trast with the presence of abundant corpora lutea and
large antral follicles in control ovaries. Ovulation does
not occur in DHEA-treated group and some of follicles
enter atretic process and oocytes in the follicle degener-
ated. Additionally, we detected characteristic theca cell
luteinization (Figure 1C and D).
PCOS ovaries were larger than control and vehicle
groups because of numerous antral follicles. Stromal
species between follicles were incompact in the cortex
layer of ovary. We observed increased medullar area
and enlarged vessels network. Vehicle group ovary
represents same morphological findings with control
ovary.Hormone assay
Female mice of 25 day old (Postnatal 25 (PN25), before
treatment), 45 day old (25 day old BalbC mice + 20 daytreatment (DHEA-treated/sesame oil-treated) or no
treatment (control group) = 45 day old) were sacrificed
at the proestrus stage (based on vaginal smears) in order
to measure gonadotropin levels during the follicular
growth phase, but not the ovulation phase. As a meas-
urement of ovarian function in the cyst pathology, serum
Estradiol (E2) and Progesterone (P) levels were evaluated
by ELISA (Figure 3A and B, respectively). The levels of
steroid hormones determined in DHEA-treated and con-
trol animals. The levels of estrogen and progesterone
examined increased after treatment with DHEA
(Figure 3A and B).Immunohistochemistry
Expression of mTOR and serine 2448–phosphorylated
form of mTOR (P-mTOR) was assessed by immuno-
histochemistry (Figure 4A–D). Generally, mTOR ex-
pression was shown mainly cytoplasmic nature of total
within granulosa cells in various stages of follicular de-
velopment in control, DHEA-treated and vehicle
group. P-mTOR expression was highly enriched in mi-
totic granulosa cells in all stage of developing follicles
in three groups. When we elevated all groups for
mTOR staining pattern, we did not detect any
Figure 3 Serum Estradiol (E2) (A) and Progesterone (P) (B) levels were evaluated by ELISA. Female mice of 25 day old (before treatment
postnatal 25-day old, PN25), 45 day old (25 day old BalbC mice + 20 day treatment (DHEA-treated/sesame oil-treated) or no treatment (control
group) = 45 day old). The levels of estradiol and progesterone examined increased after treatment with DHEA. C: Control group, DHEA: DHEA-
treated PCOS group, V: Vehicle group.
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in mitotic granulosa cells than control and vehicle
groups. There was no difference for granulosa cells be-
tween control and vehicle groups for mTOR and P-
mTOR immunostaining. We also detected cytoplasmic
mTOR immunostaining in primary and secondary
oocytes in different stage of developing follicles but
not P-mTOR (Figure 4A–D). Granulosa lutein cellsFigure 4 Expression of mTOR and serine 2448–phosphorylated form
DHEA-treated mouse ovary. mTOR expression was shown mainly cytopla
development in control, DHEA-treated and vehicle groups. P-mTOR expres
developing follicles in three groups (arrow, A–D). Negative control has noshowed moderate mTOR staining in the control group
ovary. There is no mTOR and P-mTOR immunoreac-
tivity in negative control slides (Figure 4D, insert).
Western blot
mTOR is associated with two distinct complexes,
mTORC1 and mTORC2. mTORC1 is rapamycin-sensitive
and promotes cell growth and autophagy largely throughof mTOR (P-mTOR) double staining by immunohistochemistry in
smic nature of total within granulosa cells in various stages of follicular
sion was highly enriched in mitotic granulosa cells in all stage of
staining (D, insert).
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P-P70S6K1 (by phosphorylation of P70S6K1threonine
389). mTORC2 is rapamycin-insensitive and regulates
cytoskeletal dynamics and actin organization through acti-
vation of PKCα and through phosphorylation P-PKCα (by
phosphorylation of PKCα/beta (Thr638/641)). All the data
elevated statistically and there is no statistically difference
between control and DHEA-treated PCOS mouse group
(P < 0.05).
mTOR signaling showed no difference between groups
(Figures 5A and 6A). We found that P-mTOR (serine
2448) protein level was dramatically increased in PCOS
group compared with that in control (Figures 5A and
6B). Raptor (Figures 5A and 6C) and GβL (LST8)
(Figure 6A and B) protein signaling showed no difference
between three groups (P < 0.05). mTORC2 is activated by
phosphorylation of serine-2481 region of mTOR. P-mTOR
(serine-2481) showed increased protein expression in
PCOS group than other groups (Figures 5B and 6E). Rictor
protein level was also higher in PCOS group as resemble
with P-mTOR (serine-2481) (Figures 5B and 6D) (P < 0.05).
P70S6K protein band did not show any difference
among three groups (Figure 7A and B) but mTORC1-
dependent phosphorylation of P70S6K (P-P70S6K1) was
increased in DHEA-treated group (Figure 7C and D)
(P < 0.05). There were no difference of PKCα and
P-PKCα/beta (Thr638/641 phosphorylation) signaling
(Figure 8A–D) (P < 0.05). PCNA were used detection of
proliferation difference in three groups by western blot.
We showed that PCNA signaling was increased in PCOS
group when we compared with control and vehicle
groups (Figure 9A and B) (P < 0.05).
RT-PCR
DHEA-treated, vehicle and control group ovaries express
the key components of both mammalian target of rapa-
mycin complex 1 (mTORC1) and mTORC2. Reverse
transcription polymerase chain reaction analysis of
mTORC genes showed that the key components of both
mTORC1 and mTORC2 are expressed in three groups
of ovaries. Transcripts of 2 genes common to both com-
plexes, mTOR and mLST8, are expressed in whole ovary
samples (3 unique repeats, Ov1-3). Both Raptor, anFigure 5 mTORC1 and mTORC2 protein expression in control (C), DHEessential component of mTORC1, and Rictor, essential
for mTORC2, are expressed in whole ovary in all three
groups. All mock reverse transcribed samples resulted in
no bands. β-actin were used as internal control (Figure
not shown).Discussion
In the present study we mimicked the human anovula-
tory PCOS using DHEA-treated mouse model. The
population of antral follicles increased in PCOS mouse
ovary, but there is evidence that disordered folliculogen-
esis also involves the smaller, preantral follicles [33].
Beside of increased number of growing immature fol-
licle, communication in between oocyte and granulosa
cells is disturbed. Therefore, there is a failure of selec-
tion of dominant follicle, and the number of arrested
and atretic follicles is significantly increased in polycystic
ovaries [34]. In our study, we observed excess immature
and atretic follicles at the different stage of folliculogen-
esis. Ovarian morphology and hormone status were
investigated in female rats given daily androstenedion
injections and Okutsu et al. showed that androstene-
dione administration enhances apoptosis in the inner
part of granulosa cell layers of antral follicles, which sub-
sequently leads to the formation of ovarian follicular
cysts and exposure to excess androstenedione stimulates
premature luteinization of granulosa cells, which is most
likely due to the loss of oocyte-granulosa cell communi-
cation [35]. The findings suggested here show that mice
from the DHEA group exhibited increased levels of both
serum estradiol (E2) and progesterone (P). We suggested
that after daily injection of DHEA, hyperandrogenized
environment occur the increased concentration of serum
E2 would result in unfavorable conditions for producing
follicles destined for ovulation. Previous studies work
with the same animal model, have reported a similar
hormonal regulation [16]. This hormonal profile sug-
gests an increased steroidogenic activity, which is widely
described in PCOS [1,36]. The follicles from anovulatory
women with PCOS hypersecrete E2 when compared with
size-matched follicles from normal ovaries or polycystic
ovaries from ovulatory women [36-38]. Additionally, absentA-treated PCOS (DHEA) and vehicle (V) groups. (P < 0.05).
Figure 6 mTORC1 and mTORC2 protein expression levels in control (C), DHEA-treated PCOS (DHEA) and vehicle (V) groups. (P < 0.05).
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ovulatory infertility model.
A characteristic of the ovarian morphology that was
seen in DHEA-treated mice was the presence of follicu-
lar cysts. These results demonstrate that ovarianFigure 7 P70S6K (A and B) and P-P70S6K (C and D) protein expressio
groups. (P < 0.05).follicular cysts are formed from antral follicles and that
androstenedione treatments selectively disrupt the later
stages of ovarian follicle development (follicle matur-
ation) and subsequent ovulation. Thus, the current
results demonstrate that enhanced E2 and P level is then in control (C), DHEA-treated PCOS (DHEA) and vehicle (V)
Figure 8 PKCalpha (A and B) and P-PKCα/beta (Thr638/641 phosphorylation) (C and D) protein expression in control (C), DHEA-treated
PCOS (DHEA) and vehicle (V) groups. (P < 0.05).
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the development of dominant follicles. Moreover, we
showed that exposure to excess DHEA stimulated
increased estradiol and progesterone levels. Therefore,
excess DHEA stimulation may cause to the loss of
oocyte-granulosa cell communication and degeneration
of healthy oocytes and follicle [39,40]. Additionally,
DHEA induces increased steroidogenesis in the prolifer-
ating and differentiative granulosa cells of early antral
follicles as they develop into cysts.
In our present study, mTOR and its downstream effec-
tors were elevated in DHEA-treated PCOS mouse
model. The mTORC1 and mTORC2 have crucial roles
in different pathways as energy and nutrient sensing,
metabolism, cell growth, and differentiation [41-46]. We
showed previously that mTOR is ubiquitously expressed
in mouse ovary with predominantly cytoplasmic andFigure 9 PCNA protein expression in control (C), DHEA-treated PCOSperinuclear expression in granulosa cells. However, the
P-mTOR (serine 2448) is strongly enriched within mi-
totic granulosa cells and localizes in the region of the
mitotic spindle and also near actin filament–containing
structures, including the contractile ring of cytokinesis
[27]. Here we showed mTOR signal proteins in DHEA-
treated PCOS mouse model. mTOR and P-mTOR
(Serine-2448) showed more protein expression in P
group than C and V group. Raptor and GβL (LST8) are
two major components of mTORC1 have role in cell
proliferation and differentiation. There is no difference
about Raptor and GβL (LST8) expression between three
groups. Therefore, we suggested that Raptor and GβL
(LST8) proteins have important role in activation of
mTORC1 and then stimulation of downstream proteins.
In this situation, we suggested that Serine-2448
phosphorylated form of mTOR may be responsible(DHEA) and vehicle (V) groups. (P < 0.05).
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in PCOS mouse ovary. Our PCNA western blot
results confirmed that DHEA-treated PCOS mouse
ovary showed increased proliferation compared to
other groups as shown by increased PCNA expres-
sion. P70S6K is well defined downstream signal pro-
tein of mTORC1. mTOR regulates cell growth and
proliferation functions through cytoplasmic targets
such as P70S6K. Bachmann et al. showed that mTOR
shuttles between the nucleus and cytoplasm, and
nucleocytoplasmic shuttling of mTOR is required for
the maximal activation of S6K1 [47]. mTOR stimu-
lates translation by phosphorylating P70S6 kinase and,
consequently, the 40S ribosomal protein S6 [48]. Acti-
vation of this pathway is required for FSH-mediated
induction of several follicular differentiation markers,
including luteinizing-hormone receptor (LHR), inhibin-α,
microtubule-associated protein 2D, and the PKA type IIβ
regulatory subunit [48]. Based on our results we suggested
that activation of mTORC1 has stimulatory effect on
P70S6K downstream signal protein. Therefore, P-P70S6K
protein level showed difference than P70S6K. Interestingly
in our study we detected decreased P-P70S6K protein
expression in PCOS group and suggested that P-P70S6K
might decrease in DHEA-treated PCOS mouse ovary
because of dysfunctional folliculogenesis. Namely, follicu-
lar differentiation signals with FSH stimulation cannot
show enough effect through decreased level of FSH in
PCOS. Thence, we suggested that insufficient P70S6K
activation causes the arrest of follicular development.
Thus, P-P70S6K showed decreased level in DHEA-
treated PCOS mouse ovary.
mTORC2 is composed of mTOR, Rictor, mSIN1, and
GβL (LST8), and this branch of mTOR action is resistant
to acute inhibition by rapamycin. Our study is the first to
show showed weak P-mTOR (Serine-2481) protein level
showed very weak expression in all groups, but increased
in DHEA-treated PCOS mouse ovary. Moreover, Rictor
protein level showed increased expression in PCOS mouse
ovary when we compare with control and vehicle groups.
We suggested that mTORC2 signal pathway may have im-
portant role in PCOS. PKCalpha is an important protein
which has role in cell proliferation, differentiation and
apoptosis. mTORC2 involved in the phosphorylation of
PKCalpha and in post-translational processing [49]. Abla-
tion of mTORC2 components (Rictor, Sin1 or mTOR)
abolished phosphorylation of the PKCalpha [49]. In our
study PKCalpha and its phosphorylated form P-PKCα/
beta (Thr638/641) showed same intensity for protein level
in three experimental groups. At the same time, there is
no difference between PCOS and control group for
PKCalpha and P-PKCα/beta (Thr638/641) protein levels.
Therefore we suggested that mTORC2 may use also dif-
ferent downstream signal proteins beside PKCalpha inDHEA-treated PCOS mouse ovary. We therefore sug-
gested that Rho and Akt downstream proteins of
mTORC2 may also have roles in PCOS mouse ovary.
The characteristic morphological feature of polycys-
tic ovaries in anovulatory women is accumulation of
antral follicles in the range of 2–8 mm in diameter.
Therefore follicular maturation is disturbed, resulting
in premature arrest of follicular growth. Additionally
oocyte-granulosa cells communication is also dis-
rupted and apparent failure to select a dominant fol-
licle [36]. The results presented here indicate that
mTORC1 and mTORC2 together may have important
regulatory function in PCOS mouse model. Different
abnormalities may appear depending on stress or nu-
trition and they may effect directly follicular growth.
As it is known that changes in lipid metabolism dis-
order in PCOS causes women to gain weight exces-
sively. These findings in PCOS suggest a direct
relationship between the energy metabolism of cells
and the mTOR signaling mechanisms. Both stress
and eating disorders have seen in PCOS (as com-
monly observed in patients with PCOS suffer from
obesity) as well as hormonal imbalance. The mechan-
ism of mTOR by affecting the development of cystic
structures, and can cause anovulation. Therefore we
suggested that the increase in mTOR activation
(mTORC1 and mTORC2) causes increased granulosa
cell proliferation. In another study, blockade of cen-
tral mTOR signaling by rapamycin caused decreased
LH secretion [26]. Consequently, we suggested that
Rapamycin (the inhibitor of mTOR) may be a com-
pensatory mechanism attempting to increase protein
synthesis and regulate stimulation of luteinized hor-
mone secretion for preventing or treating anovulatory
PCOS.
PCOS patients have high levels of LH and show an-
ovulatory follicles in their ovary. This might be due
either to abnormalities in LH secretion or to an aug-
mentation of the LH stimulus through hyperinsuline-
mia and/or hyperandrogenemia [50]. Phosphorylation
of mTOR in PCOS mouse model may be potentially
due to estrogens or other derivatives. So it is neces-
sary to further investigate how DHEA is related, dir-
ectly and indirectly mTOR signal mechanisms effect
to folliculogenesis and ovulation process.
In summary, we have found that DHEA increases
mTORC1 and mTORC2 expression in mouse ovary.
It appears, since DHEA increased mTOR expression
in proliferative and differentiative-stage cells (prema-
ture luteinization of granulosa cells), mTOR signal
pathways in DHEA metabolism might play important
roles in the PCOS mouse ovary that results in dis-
turbance of the dominant follicle selection and leads
to abnormal follicular development and cystogenesis.
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